Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 128) Show all publications
Zethelius, B., Attelind, S., Westman, G., Ljung, R. & Sundstrom, A. (2024). Pulmonary embolism after SARS-CoV-2 vaccination. Vaccine: X, 21, Article ID 100571.
Open this publication in new window or tab >>Pulmonary embolism after SARS-CoV-2 vaccination
Show others...
2024 (English)In: Vaccine: X, E-ISSN 2590-1362, Vol. 21, article id 100571Article in journal (Refereed) Published
Abstract [en]

Background: During the COVID-19 vaccination campaign in Sweden, pulmonary embolism (PE) was a frequently reported suspected serious adverse drug reaction. The aim was to estimate risk of PE following vaccination for COVID-19 in the Swedish population aged 18 to 84 years.

Methods: Population-based cohort study using the CoVacSafe-SE established platform including national registers. PE-case definition: Individuals discharged from inpatient-care or visiting specialized outpatient-care with a main diagnosis of PE occurring between 27-Dec-2020 and 31-Dec-2022 without simultaneous diagnosis of COVID-19 infection. Time-to-event analysis was performed using multi-variable Cox' proportional hazard's models. Hazard Ratios (HR) adjusted for age, sex and co-morbidities were modelled. The vaccines were BNT162b2/Comirnaty (R), mRNA1273/Spikevax (R) and ChAdOx1 nCoV-19/Vaxzevria (R) without regard to variants. Doses number one to five were studied.

Results: Eighty percent of the study-population (approximate to 6.1 million people) received at least two doses of COVID-19 vaccine. A total of 12,456 cases of PE were identified. Twenty-eight days after vaccinations we observed 99 cases after 701,455 1st doses of ChAdOx1 nCoV-19, HRadj, 1.29 (95%-CI, 1.05-1.59). Corresponding for BNT162b2 was 361 cases after 4,708,284 1st doses of BNT162b2 HR adj of 1.19 (95%-CI, 1.06-1.34) driven by age group 65-84; HR adj, 1.24 (95%-CI, 1.07-1.44). No increased risks were observed for mRNA1273.

Conclusion: In this nation-wide study, no strong associations were found between COVID-19 vaccinations and pulmonary embolism. Small increases in relative risk for the earliest doses of vaccines may be associated with prioritizing the frailest groups of people in the vaccination campaign, thus selection bias or unmeasured residual confounding is possible.

Place, publisher, year, edition, pages
Elsevier, 2024
Keywords
COVID-19 vaccines, Vaccine safety, Primary vaccinations, Booster vaccinations, Pulmonary embolism, Public health, Regulatory science
National Category
Public Health, Global Health and Social Medicine Infectious Medicine Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:uu:diva-542251 (URN)10.1016/j.jvacx.2024.100571 (DOI)001339614600001 ()39474208 (PubMedID)
Available from: 2024-11-28 Created: 2024-11-28 Last updated: 2025-02-20Bibliographically approved
Lin, E., Garmo, H., Hagström, E., Van Hemelrijck, M., Adolfsson, J., Stattin, P., . . . Crawley, D. (2023). Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden. British Journal of Cancer, 128(5), 814-824
Open this publication in new window or tab >>Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
Show others...
2023 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 128, no 5, p. 814-824Article in journal (Refereed) Published
Abstract [en]

Background

Gonadotropin-releasing hormone agonists (GnRH) used in prostate cancer (PCa) are associated with atherogenic dyslipidaemia. It can be assumed that GnRH need to be used with greater caution in men with type 2 diabetes mellitus (T2DM). This study investigated association of GnRH with atherogenic lipids (AL) in PCa men with T2DM.

Methods

Two cohorts including 38,311 men with 11 years follow-up based on Swedish national registers were defined (PCa-Exposure cohort and GnRH-Exposure cohort). Based on European guidelines on cardiovascular diseases (CVD), primary outcomes were defined as: 1.0 mmol/L increase in AL and lipid-lowering therapy (LLT) intensification. We used Cox proportional-hazards models and Kaplan–Meier curves to assess the association.

Results

There was an association between GnRH and increased AL (i.e., triglyceride, PCa-Exposure cohort: HR 1.77, 95% CI 1.48–2.10; GnRH-Exposure cohort: HR 1.88, 95% CI 1.38–2.57). There was also an association between PCa diagnosis and increased AL. In contrast, no association between LLT intensification and GnRH was found.

Conclusion

In this large population-based study, men with T2DM on GnRH for PCa had an increased risk of increased atherogenic lipids. These results highlight the need to closely monitor lipids and to be ready to intensify lipid-lowering therapy in men with T2DM on GnRH for PCa.

Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Cardiology and Cardiovascular Disease Cancer and Oncology Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-491313 (URN)10.1038/s41416-022-02091-z (DOI)000899466600002 ()36522475 (PubMedID)
Funder
Swedish Research Council, 2017-00847Swedish Cancer Society, 16 0700The Cancer Society in Stockholm
Available from: 2022-12-20 Created: 2022-12-20 Last updated: 2025-02-10Bibliographically approved
Williamson, A., Norris, D. M., Yin, X., Broadaway, K. A., Moxley, A. H., Vadlamudi, S., . . . Langenberg, C. (2023). Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake. Nature Genetics, 55(6), 973-983
Open this publication in new window or tab >>Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake
Show others...
2023 (English)In: Nature Genetics, ISSN 1061-4036, E-ISSN 1546-1718, Vol. 55, no 6, p. 973-983Article in journal (Refereed) Published
Abstract [en]

Distinct tissue-specific mechanisms mediate insulin action in fasting and postprandial states. Previous genetic studies have largely focused on insulin resistance in the fasting state, where hepatic insulin action dominates. Here we studied genetic variants influencing insulin levels measured 2 h after a glucose challenge in >55,000 participants from three ancestry groups. We identified ten new loci (P < 5 × 10-8) not previously associated with postchallenge insulin resistance, eight of which were shown to share their genetic architecture with type 2 diabetes in colocalization analyses. We investigated candidate genes at a subset of associated loci in cultured cells and identified nine candidate genes newly implicated in the expression or trafficking of GLUT4, the key glucose transporter in postprandial glucose uptake in muscle and fat. By focusing on postprandial insulin resistance, we highlighted the mechanisms of action at type 2 diabetes loci that are not adequately captured by studies of fasting glycemic traits.

Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-505815 (URN)10.1038/s41588-023-01408-9 (DOI)001005292100001 ()37291194 (PubMedID)
Available from: 2023-06-21 Created: 2023-06-21 Last updated: 2024-03-15Bibliographically approved
Broadaway, K. A., Yin, X., Williamson, A., Parsons, V. A., Wilson, E. P., Moxley, A. H., . . . Mohlke, K. L. (2023). Loci for insulin processing and secretion provide insight into type 2 diabetes risk.. American Journal of Human Genetics, 110(2), 284-299
Open this publication in new window or tab >>Loci for insulin processing and secretion provide insight into type 2 diabetes risk.
Show others...
2023 (English)In: American Journal of Human Genetics, ISSN 0002-9297, E-ISSN 1537-6605, Vol. 110, no 2, p. 284-299Article in journal (Refereed) Published
Abstract [en]

Insulin secretion is critical for glucose homeostasis, and increased levels of the precursor proinsulin relative to insulin indicate pancreatic islet beta-cell stress and insufficient insulin secretory capacity in the setting of insulin resistance. We conducted meta-analyses of genome-wide association results for fasting proinsulin from 16 European-ancestry studies in 45,861 individuals. We found 36 independent signals at 30 loci (p value < 5 × 10-8), which validated 12 previously reported loci for proinsulin and ten additional loci previously identified for another glycemic trait. Half of the alleles associated with higher proinsulin showed higher rather than lower effects on glucose levels, corresponding to different mechanisms. Proinsulin loci included genes that affect prohormone convertases, beta-cell dysfunction, vesicle trafficking, beta-cell transcriptional regulation, and lysosomes/autophagy processes. We colocalized 11 proinsulin signals with islet expression quantitative trait locus (eQTL) data, suggesting candidate genes, including ARSG, WIPI1, SLC7A14, and SIX3. The NKX6-3/ANK1 proinsulin signal colocalized with a T2D signal and an adipose ANK1 eQTL signal but not the islet NKX6-3 eQTL. Signals were enriched for islet enhancers, and we showed a plausible islet regulatory mechanism for the lead signal in the MADD locus. These results show how detailed genetic studies of an intermediate phenotype can elucidate mechanisms that may predispose one to disease.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
GWAS, colocalization, conditional, eQTL, enhancer, fine-mapping, meta-analysis, proinsulin, signal, type 2 diabetes
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-496303 (URN)10.1016/j.ajhg.2023.01.002 (DOI)000951221200001 ()36693378 (PubMedID)
Available from: 2023-02-09 Created: 2023-02-09 Last updated: 2023-04-13Bibliographically approved
Zanetti, D., Stell, L., Gustafsson, S., Abbasi, F., Tsao, P. S., Knowles, J. W., . . . Assimes, T. L. (2023). Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts. Diabetologia, 66(9), 1643-1654
Open this publication in new window or tab >>Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts
Show others...
2023 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 66, no 9, p. 1643-1654Article in journal (Refereed) Published
Abstract [en]

Aims/hypothesis The euglycaemic-hyperinsulinaemic clamp (EIC) is the reference standard for the measurement of whole-body insulin sensitivity but is laborious and expensive to perform. We aimed to assess the incremental value of high-through-put plasma proteomic profiling in developing signatures correlating with the M value derived from the EIC.

Methods We measured 828 proteins in the fasting plasma of 966 participants from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study and 745 participants from the Uppsala Longitudinal Study of Adult Men (ULSAM) using a high-throughput proximity extension assay. We used the least absolute shrinkage and selection operator (LASSO) approach using clinical variables and protein measures as features. Models were tested within and across cohorts. Our primary model performance metric was the proportion of the M value variance explained (R-2).

Results A standard LASSO model incorporating 53 proteins in addition to routinely available clinical variables increased the M value R-2 from 0.237 (95% CI 0.178, 0.303) to 0.456 (0.372, 0.536) in RISC. A similar pattern was observed in ULSAM, in which the M value R-2 increased from 0.443 (0.360, 0.530) to 0.632 (0.569, 0.698) with the addition of 61 proteins. Models trained in one cohort and tested in the other also demonstrated significant improvements in R-2 despite differences in baseline cohort characteristics and clamp methodology (RISC to ULSAM: 0.491 [0.433, 0.539] for 51 proteins; ULSAM to RISC: 0.369 [0.331, 0.416] for 67 proteins). A randomised LASSO and stability selection algorithm selected only two proteins per cohort (three unique proteins), which improved R-2 but to a lesser degree than in standard LASSO models: 0.352 (0.266, 0.439) in RISC and 0.495 (0.404, 0.585) in ULSAM. Reductions in improvements of R-2 with randomised LASSO and stability selection were less marked in cross-cohort analyses (RISC to ULSAM R-2 0.444 [0.391, 0.497]; ULSAM to RISC R-2 0.348 [0.300, 0.396]). Models of proteins alone were as effective as models that included both clinical variables and proteins using either standard or randomised LASSO. The single most consistently selected protein across all analyses and models was IGF-binding protein 2.

Conclusions/interpretation A plasma proteomic signature identified using a standard LASSO approach improves the cross-sectional estimation of the M value over routine clinical variables. However, a small subset of these proteins identified using a stability selection algorithm affords much of this improvement, especially when considering cross-cohort analyses. Our approach provides opportunities to improve the identification of insulin-resistant individuals at risk of insulin resistance-related adverse health consequences.

Place, publisher, year, edition, pages
Springer, 2023
Keywords
Euglycaemic-hyperinsulinaemic clamp, Insulin resistance, Insulin sensitivity, LASSO, Plasma proteomics, Population study, Stability selection
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-512272 (URN)10.1007/s00125-023-05946-z (DOI)001012589300002 ()37329449 (PubMedID)
Funder
Swedish Heart Lung Foundation
Available from: 2023-09-26 Created: 2023-09-26 Last updated: 2023-09-26Bibliographically approved
Lin, E., Garmo, H., Van Hemelrijck, M., Zethelius, B., Stattin, P., Hagström, E., . . . Crawley, D. (2022). Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Network Open, 5(8), Article ID e2225600.
Open this publication in new window or tab >>Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
Show others...
2022 (English)In: JAMA Network Open, E-ISSN 2574-3805, Vol. 5, no 8, article id e2225600Article in journal (Refereed) Published
Abstract [en]

IMPORTANCE Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of CVD. OBJECTIVE To evaluate the association between GnRH agonist use, PCa diagnosis per se, and CVD risk in men with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS This nationwide population-based cohort study identified men with type 2 diabetes by use of data in the Prostate Cancer Data Base Sweden version 4.1 and the Swedish National Diabetes Register, with longitudinal data from 2006 to 2016. These data were used to create 2 cohorts, 1 including men with and without PCa and the other including men with PCa who received and did not receive GnRH agonists. Data analysis was conducted from January 2006 to December 2016. EXPOSURES Treatment with GnRH agonists and PCa diagnosis were the primary exposures. MAIN OUTCOMES AND MEASURES Primary outcome was a 10% increase in predicted 5-year CVD risk score. Secondary outcome was worsening hypertension as defined by the European Society of Hypertension Guidelines. Cox proportional hazards regression models were used to analyze the association. RESULTS The PCa exposure cohort included 5714 men (median [IQR] age, 72.0 [11.0]), and the non-PCa cohort included 28 445 men without PCa (median [IQR] age, 72.0 [11.0]). The GnRH agonist-exposure cohort included 692 men with PCa who received a GnRH agonist, compared with 3460 men with PCa who did not receive a GnRH agonist. Men with PCa receiving GnRH agonists had an increased estimated 5-year CVD risk score compared with men without PCa (hazard ratio [HR], 1.25; 95% CI, 1.16-1.36) and compared with men with PCa not receiving GnRH agonists (HR, 1.53; 95% CI, 1.35-1.74). Men receiving GnRH agonists had decreased blood pressure compared with men without PCa (HR, 0.70; 95% CI, 0.61-0.80) and compared with men with PCa not receiving GnRH agonists (HR, 0.68; 95% CI, 0.56-0.82). CONCLUSIONS AND RELEVANCE In this population-based cohort study, there was an increased risk of CVD in men with type 2 diabetes who received a GnRH agonist for PCa. These findings highlight the need to closely control CVD risk factors in men with type 2 diabetes treated with GnRH agonists. The association between GnRH agonist use and decreased blood pressure levels warrants further study.

Place, publisher, year, edition, pages
American Medical Association (AMA)American Medical Association (AMA), 2022
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-482672 (URN)10.1001/jamanetworkopen.2022.25600 (DOI)000839632900002 ()35939302 (PubMedID)
Funder
Swedish Research Council, 2017-00847Swedish Cancer Society, 16 0700
Available from: 2022-09-15 Created: 2022-09-15 Last updated: 2024-01-15Bibliographically approved
Ljung, R., Grünewald, M., Sundström, A., Thunander Sundbom, L. & Zethelius, B. (2022). Comparison of years of life lost to 1,565 suicides versus 10,650 COVID-19 deaths in 2020 in Sweden: four times more years of life lost per suicide than per COVID-19 death. Upsala Journal of Medical Sciences, 127(1), Article ID e8533.
Open this publication in new window or tab >>Comparison of years of life lost to 1,565 suicides versus 10,650 COVID-19 deaths in 2020 in Sweden: four times more years of life lost per suicide than per COVID-19 death
Show others...
2022 (English)In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 127, no 1, article id e8533Article in journal (Refereed) Published
Abstract [en]

Background: The burden of disease from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is large; however, suicide affects the population year after year. From a public health perspective, it is important to not neglect contributors to the total burden of disease. The aim of this paper is to compare years of life lost (YLL) to suicide with those lost to coronavirus disease 2019 (COVID-19).

Methods: A nationwide cohort study in 2020, in Sweden. YLL was measured as the sex- and age-specific remaining life expectancy at the time of the person’s death based on the death risks that pertained to the Swedish population in 2019. YLL to suicide was compared to YLL to COVID-19 and presented by sex and age groups. Suicide deaths in 2020 were estimated as the annual average of suicides in 2015–2019.

Results: Annual average of suicide was 1,565, whereof 1,076 (68.8%) men and 489 (31.2%) women. In 2020, 10,650 persons died of COVID-19, whereof 5,681 (53.3%) men and 4,969 (46.7%) women. Estimated total YLL to suicide and COVID-19 in 2020 was 53,237 and 90,116, respectively. The COVID-19 YLL to suicide YLL ratio in 2020 was 1.69 (90,116/53,237). Men accounted for 67.1% of suicide YLL and of 56.4% of COVID-19 YLL. Those 44 years or younger accounted for 60.3% of suicide YLL and 3.9% of COVID-19 YLL. Those 75 years and older accounted for 2.9% of suicide YLL and 60.9% of COVID-19 YLL. On average, each suicide generates 34 YLL (53,237/1,565), and each COVID-19 death generates 8.5 YLL (90,116/10,650).

Conclusions: YLL to suicide affects Sweden year after year, foremost attributable to the younger age groups, whereas YLL to COVID-19 is foremost attributable to the elderly. On average, each suicide generates four times more YLL than a COVID-19 death. Enormous efforts and resources have been put on tackling the pandemic, and without these, the burden would probably have been much larger. However, from a public health perspective, it is important to not neglect other contributors to the total burden of disease where national efforts also may have an impact.

Place, publisher, year, edition, pages
Upsala Medical SocietyUppsala Medical Society, 2022
Keywords
Life expectancy, SARS-CoV-2, suicide, psychiatric disorders, burden of disease, public health
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:uu:diva-479924 (URN)10.48101/ujms.v127.8533 (DOI)000811348300001 ()35722184 (PubMedID)
Available from: 2022-07-05 Created: 2022-07-05 Last updated: 2025-02-20Bibliographically approved
Lind, L., Zethelius, B. & Byberg, L. (2022). Self-reported physical activity and different cardiovascular diseases-Results from updated measurements over 40 years. PLOS ONE, 17(6), Article ID e0269402.
Open this publication in new window or tab >>Self-reported physical activity and different cardiovascular diseases-Results from updated measurements over 40 years
2022 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 17, no 6, article id e0269402Article in journal (Refereed) Published
Abstract [en]

Background Self-reported leisure-time physical activity (PA) has previously been linked to risk of cardiovascular disease (CVD). We now aim to investigate the strength of associations between PA and different CVDs and how the risk varies with age. Methods PA and traditional CV risk factors assessed by a questionnaire on a four-level scale in 2,175 men at age 50 years in the ULSAM study. Examinations were thereafter repeated at ages 60, 70, and 77. Results During 40 years follow-up, 883 individuals experienced a CVD (myocardial infarction, stroke, or heart failure). Using data from all four examinations, a graded reduction in risk of incident CVD was seen with increasing PA (HR 0.84, 95%CI; 0.77-0.93, p= 0.001 for trend test). PA was related to myocardial infarction (HR 0.84, 95%CI; 0.74-0.95, 490 cases), heart failure (HR 0.79, 95%CI; 0.68-0.91, 356 cases), but only of borderline significance vs ischemic stroke (HR 0.85, 95%CI; 0.73-1.00, 315 cases) when the CVDs were analyzed separately. Adjusting for traditional CV risk factors attenuated all relationships between PA and incident CVD, and PA did not improve discrimination of CVD when added on top of risk factors. When 10-year risk was calculated from each examination, age 70 was the time-point when PA was most closely related to incident CVD. Conclusion Leisure-time physical activity is related to future CVD. This was most evident at 70 years of age. If a causal relationship between self-reported PA and CVD exists, this relationship might to a major degree be mediated by traditional risk factors.

Place, publisher, year, edition, pages
Public Library of Science (PLoS)PUBLIC LIBRARY SCIENCE, 2022
National Category
Cardiology and Cardiovascular Disease Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-485360 (URN)10.1371/journal.pone.0269402 (DOI)000843567600083 ()35657994 (PubMedID)
Available from: 2022-09-23 Created: 2022-09-23 Last updated: 2025-02-10Bibliographically approved
Lind, L., Zethelius, B., Lindberg, E., Pedersen, N. L. & Byberg, L. (2021). Changes in leisure-time physical activity during the adult life span and relations to cardiovascular risk factors-Results from multiple Swedish studies. PLOS ONE, 16(8), Article ID e0256476.
Open this publication in new window or tab >>Changes in leisure-time physical activity during the adult life span and relations to cardiovascular risk factors-Results from multiple Swedish studies
Show others...
2021 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 16, no 8, article id e0256476Article in journal (Refereed) Published
Abstract [en]

Objective To evaluate how self-reported leisure-time physical activity (PA) changes during the adult life span, and to study how PA is related to cardiovascular risk factors using longitudinal studies. Methods Several Swedish population-based longitudinal studies were used in the present study (PIVUS, ULSAM, SHE, and SHM, ranging from hundreds to 30,000 participants) to represent information across the adult life span in both sexes. Also, two cross-sectional studies were used as comparison (EpiHealth, LifeGene). PA was assessed by questionnaires on a four or five-level scale. Results Taking results from several samples into account, an increase in PA from middle-age up to 70 years was found in males, but not in females. Following age 70, a decline in PA was seen. Young adults reported both a higher proportion of sedentary behavior and a higher proportion high PA than the elderly. Females generally reported a lower PA at all ages. PA was mainly associated with serum triglycerides and HDL-cholesterol, but also weaker relationships with fasting glucose, blood pressure and BMI were found. These relationships were generally less strong in elderly subjects. Conclusion Using data from multiple longitudinal samples the development of PA over the adult life span could be described in detail and the relationships between PA and cardiovascular risk factors were portrayed. In general, a higher or increased physical activity over time was associated with a more beneficial cardiovascular risk factor profile, especially lipid levels.

Place, publisher, year, edition, pages
Public Library of Science (PLoS)Public Library of Science (PLoS), 2021
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:uu:diva-455485 (URN)10.1371/journal.pone.0256476 (DOI)000686373300092 ()34411192 (PubMedID)
Available from: 2021-10-18 Created: 2021-10-18 Last updated: 2025-02-20Bibliographically approved
Lin, E., Garmo, H., Van Hemelrijck, M., Adolfsson, J., Stattin, P., Zethelius, B. & Crawley, D. (2021). Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer, 21(1), Article ID 1259.
Open this publication in new window or tab >>Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
Show others...
2021 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 21, no 1, article id 1259Article in journal (Refereed) Published
Abstract [en]

Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. Methods Nationwide population-based cohort study in the Swedish National Diabetes Register and Prostate Cancer data Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. Worsening diabetes control was the primary outcome, defined as: 1) HbA1c rose to 58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of antidiabetic drugs or switch to insulin. We also combined all above definitions. Cox proportional hazards regression was used to analyze the association. Results There were 5714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free men with T2DM with similar baseline characteristics. Diabetes control was worse in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13-1.34) as well as compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39-1.80), when we defined the worsening control of diabetes by combining all definitions above. Conclusion Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The findings highlight the need to closely monitor diabetes control in men with T2DM and PCa starting GnRH.

Place, publisher, year, edition, pages
BioMed Central (BMC)BMC Cancer, 2021
Keywords
Prostate cancer diagnosis, Gonadotropin-releasing hormone agonists, Diabetes
National Category
Endocrinology and Diabetes Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-460220 (URN)10.1186/s12885-021-08941-y (DOI)000721964800001 ()34809595 (PubMedID)
Funder
Swedish Research Council, 2017-00847Swedish Cancer Society, 16 0700
Available from: 2021-12-10 Created: 2021-12-10 Last updated: 2024-07-04Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-1738-0834

Search in DiVA

Show all publications